Author:
Torrente-López Anabel,Hermosilla Jesús,Pérez-Robles Raquel,Salmerón-García Antonio,Cabeza José,Navas Natalia
Subject
Spectroscopy,Analytical Chemistry
Reference45 articles.
1. European Medicines Agency. Nivolumab: Summary of Product Characteristics., https://www.ema.europa.eu/en/documents/product-information/opdivo-epar-product-information_en.pdf (accessed July 12, 2021).
2. L.A. Raedler, Opdivo (Nivolumab): Second PD-1 Inhibitor Receives FDA Approval for Unresectable or Metastatic Melanoma., Am. Heal. Drug Benefits. 8 (2015) 180–3. chrome-extension://dagcmkpagjlhakfdhnbomgmjdpkdklff/enhanced-reader.html?pdf=https%3A%2F%2Fbrxt.mendeley.com%2Fdocument%2Fcontent%2F95d92e80-a042-3bff-a804-f61cdfb0d7a1 (accessed December 3, 2020).
3. FDA Approval summary: nivolumab for the treatment of metastatic non-small cell lung cancer with progression on or after platinum-based chemotherapy;Kazandjian;Oncologist.,2016
4. FDA approval summary: nivolumab in advanced renal cell carcinoma after anti-angiogenic therapy and exploratory predictive biomarker analysis;Xu;Oncologist.,2017
5. FDA approval summary: nivolumab for the treatment of relapsed or progressive classical hodgkin lymphoma;Kasamon;Oncologist.,2017
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献